RT @doctorRBC: SELECT-AXIS 2 trial demonstrated efficacy and safety of upadacitinib in treatment of non-radiographic axS
Tweet Content
SELECT-AXIS 2 trial demonstrated efficacy and safety of upadacitinib in treatment of non-radiographic axSpA. ASAS40 at week 14 (45% vs. 23% placebo). No MACE, VTEs, IBD, death.
@RheumNow #EULAR2022 ABST#OP0016 https://t.co/vyky0JJJjS
Show on Archive Page
On
Display in Search Results
On
PDQ
Off